Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals gained 0.220% compared to yesterday.
The stock is one of the favorites of our community with 31 Buy predictions and 1 Sell predictions.
With a target price of 27 € there is a slightly positive potential of 18.37% for Acadia Pharmaceuticals compared to the current price of 22.81 €.
Our community identified positive and negative aspects for Acadia Pharmaceuticals stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Acadia Pharmaceuticals stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | 0.220% | 2.241% | -1.383% | 35.331% | -1.808% | 41.589% | -48.017% |
| Ironwood Pharmaceuticals | 0.000% | -9.794% | 14.379% | -20.455% | 31.579% | -66.072% | -63.351% |
| Novocure Ltd | -4.380% | 3.488% | 7.181% | -54.591% | 7.322% | -86.197% | -91.552% |
| Iovance Biotherapeutics Inc. | -0.150% | -1.534% | 9.357% | -67.049% | -13.427% | -64.125% | -94.958% |
Comments
ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $40.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
Show more
Ratings data for ACAD provided by MarketBeat